Castle Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CSTL and other ETFs, options, and stocks.

About CSTL

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. 

CEO
Derek J. Maetzold
CEODerek J. Maetzold
Employees
761
Employees761
Headquarters
Friendswood, Texas
HeadquartersFriendswood, Texas
Founded
2007
Founded2007
Employees
761
Employees761

CSTL Key Statistics

Market cap
1.12B
Market cap1.12B
Price-Earnings ratio
-84.98
Price-Earnings ratio-84.98
Dividend yield
Dividend yield
Average volume
400.62K
Average volume400.62K
High today
$38.88
High today$38.88
Low today
$37.83
Low today$37.83
Open price
$38.07
Open price$38.07
Volume
514.06K
Volume514.06K
52 Week high
$40.61
52 Week high$40.61
52 Week low
$14.59
52 Week low$14.59

Stock Snapshot

As of today, Castle Biosciences(CSTL) shares are valued at $38.25. The company's market cap stands at 1.12B, with a P/E ratio of -84.98.

On 2025-12-10, Castle Biosciences(CSTL) stock traded between a low of $37.83 and a high of $38.88. Shares are currently priced at $38.25, which is +1.1% above the low and -1.6% below the high.

The Castle Biosciences(CSTL)'s current trading volume is 514.06K, compared to an average daily volume of 400.62K.

In the last year, Castle Biosciences(CSTL) shares hit a 52-week high of $40.61 and a 52-week low of $14.59.

In the last year, Castle Biosciences(CSTL) shares hit a 52-week high of $40.61 and a 52-week low of $14.59.

CSTL News

TipRanks 19h
Castle announces publication of consensus paper on DecisionDx-Melanoma test

Castle Biosciences (CSTL) announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Exp...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CSTL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.